Evidence map›Paper›PMID 21955044›Full record

ArticleJournal of chemical information and modeling2011

Discovery of novel checkpoint kinase 1 inhibitors by virtual screening based on multiple crystal structures.

Yan Li, Dong Joon Kim, Weiya Ma, Ronald A Lubet, Ann M Bode, Zigang Dong

Abstract read
In one paragraph

Article in Journal of chemical information and modeling, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Docking Screens for Novel Ligands Conferring New Biology.Journal of medicinal chemistry · 2016
    Review
  4. Statistical analysis of EGFR structures' performance in virtual screening.Journal of computer-aided molecular design · 2015
    Article
  5. Article
  6. Article
  7. Receptor-ligand molecular docking.Biophysical reviews · 2014
    Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yan LiThe Hormel Institute, University of Minnesota, Austin, Minnesota 55912, USA.
Dong Joon Kim
Weiya Ma
Ronald A Lubet
Ann M Bode
Zigang Dong

Funding

Anticarcinogenic Mechanisms of Tea ConstituentsR01CA081064 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI DONG, ZIGANG · 1999 to 2007
$1.9M
Anticarcinogenic Mechanisms of Tea ConstituentsR37CA081064 · NCI · UNIVERSITY OF MINNESOTA · PI DONG, ZIGANG · 2008 to 2012
$1.5M
NCI NIH HHS HHSN-261200533001C-NO1-CN-53301NCI NIH HHS N01 CN053301NCI NIH HHS R01 CA081064NCI NIH HHS R37 CA081064
6 · The paper itself

Abstract

Incorporating receptor flexibility is considered crucial for improvement of docking-based virtual screening. With an abundance of crystallographic structures freely available, docking with multiple crystal structures is believed to be a practical approach to cope with protein flexibility. Here we describe a successful application of the docking of multiple structures to discover novel and potent Chk1 inhibitors. Forty-six Chk1 structures were first compared in single structure docking by predicting the binding mode and recovering known ligands. Combinations of different protein structures were then compared by recovery of known ligands and an optimal ensemble of Chk1 structures were selected. The chosen structures were used in the virtual screening of over 60 000 diverse compounds for Chk1 inhibitors. Six novel compounds ranked at the top of the hits list were tested experimentally, and two of these compounds inhibited Chk1 activity-the best with an IC(50) value of 9.6 μM. Further study indicated that achieving a better enrichment and identifying more diverse compounds was more likely using multiple structures than using only a single structure even when protein structures were randomly selected. Taking into account conformational energy difference did not help to improve enrichment in the top ranked list.

Indexed as

User-Computer InterfaceAdenosine TriphosphateAlgorithmsBinding SitesCheckpoint Kinase 1Cluster AnalysisComputational BiologyCrystallography, X-RayDatabases, ProteinDrug DesignDrug DiscoveryHumansInhibitory Concentration 50LigandsModels, MolecularProtein BindingAdenosine TriphosphateCheckpoint Kinase 1CHEK1 protein, humanLigandsProtein Kinase InhibitorsProtein Kinases

Identifiers

PMID21955044
PMCPMC3244973

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.